The landmark DMT and psilocybin-like prodrug, psilacetin, patch formulations are designed for patient comfort and useability. The patch design could provide a non-invasive and dose-controlled method of treatment for substance use disorders, PTSD and depression TAMPA, Fla., Sept. 14, 2022 /PRNewswire/ — Psilera Inc. (“Psilera”), a biopharmaceutical company optimizing next-generation mental health…

Source

Previous articleMindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
Next articleSep 13, 2022, 16:50 ETMINDCURE Announces Financial Results for Fiscal 2022VANCOUVER, BC, Sept. 13, 2022 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) today announced its financial results for the three and twelve months…